Literature DB >> 122889

Molecular structural studies of human factor VIII.

P A McKee, J C Andersen, M E Switzer.   

Abstract

Neither normal nor hemophilic factor VIII protein enters a 5% sosium dodecyl sulfate gel; on reduction, however, a single 195 000-molecular-weight peptide is observed. Hemophilic and normal factor VIII contain carbohydrate and appear identical in subunit molecular weight, electrical charge, and major antigenic determinants. Thrombin activation and inactivation of factor VIII does not detectably change the subunit molecular weight. Trypsin causes similar activity changes and obviously cleaves the factor VIII subunit. Human plasmin destroys factor VIII procoagulant activity and degrades the factor VIII subunit to 103 000-, 88 000-, and 17 000-molecular-weight peptides. Both normal and hemophilic factor VIII as well as thrombin-inactivated factor VIII support ristocetin-induced platelet aggregation. Purified factor VIII chromatographed on 4% agarose in 1.0 M sodium chloride shows no dissociation of the procoagulant activity from the void volume protein. Gel chromatography on 4% agarose in 0.25 M calcium chloride results in a procoagulant activity peak removed from the void volume protein; both peaks contain protein which does not enter a 5% SDS gel, but on reduction a 195 000-molecular-weight subunit band is observed for each. Both the void volume protein peak and the procoagulant activity peak from the 0.25 M calcium chloride-agarose gel column support ristocetin-induced platelet aggregation. After removal of calcium, a small amount of procoagulant activity is present only in the void volume peak. These data suggest that both the procoagulant and von Willebrand activities are on the same molecule. Thus our previous conclusion remains the same: human factor VIII is a large glycoprotein composed of identical 195 000-molecular-weight subunits jointed by disulfide bonds and is responsible for both antihemophilic and von Willebrand activities in human plasma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 122889     DOI: 10.1111/j.1749-6632.1975.tb53319.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  Effect of phospholipases on factor-VIII activity.

Authors:  R Ananthakrishnan; S D'Souza
Journal:  Hum Genet       Date:  1978-01-19       Impact factor: 4.132

Review 3.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Monoclonal antibodies against human factor VIII molecular neutralize antihemophilic factor and ristocetin cofactor activities.

Authors:  B Sola; P Avner; Y Sultan; C Jeanneau; P Maisonneuve
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

Review 5.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

6.  Immunohistochemical localisation of factor VIII-related antigen in Hodgkin's disease.

Authors:  J Crocker; P J Smith
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

7.  Factor VIII as a marker of endothelial cells in follicular carcinoma of the thyroid.

Authors:  H R Harach; B Jasani; E D Williams
Journal:  J Clin Pathol       Date:  1983-09       Impact factor: 3.411

8.  Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

9.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

10.  Effect of dextran on factor VIII (antihemophilic factor) and platelet function.

Authors:  M Aberg; U Hedner; S E Bergentz
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.